cyrilzakka/clinical-trials huggingface dataset:
Soft Tissue Augmentation Around Dental Implant

Patients were randomly distributed into two groups (G1 and G2), all patients were treated by a submerged dental implant protocol and free gingival graft (FGG) harvested from the palate as follows:

* Group 1 (G1), received the FGG two months before implant placement.
* Group 2 (G2), received the FGG at the time of second-stage surgery (i.e. at the time of healing abutment placement).

All periodontal and radiographic assessments were done by the same operator who was neither involved in the evaluation nor the distribution process. The operator did all the evaluation steps and was completely blinded to the treatment protocol.

In this investigation, a randomized clinical trial was employed. The patient's randomization was completed by one of the department's senior residents, who was not involved in the trial and was unaware of any relevant treatment plan. A computer-generated randomization list used a randomization table to perform the randomization (SPSS v23.0). Patients were randomly distributed into two groups (G1 and G2), all patients were treated by a submerged dental implant protocol and FGG harvested from the palate. All patients received a thorough description of all procedures involved in the study. Signing a written consent was mandatory for being enrolled in the study. Complete medical and dental histories were recorded for all patients and complete clinical intraoral and extraoral examinations were done for all patients.

Selected patients were questioned about the cause and time of extractions, whether extractions were because of periodontal disease, dental decay or other causes. Previous experiences with dental procedures were also discussed. Intraoral photographs were taken to record the existing condition of teeth and mucosa before implant placement.

Eligibility Criteria:
Inclusion Criteria:

* Age: 21 years or older
* Systemic Condition: Healthy
* Keratinized Mucosa Width: Less than 2mm at the intended implant site
* Bucco-lingual Bone Width: At least 5.5 mm in a single edentulous space
* Mesio-distal Distance: At least 7 mm between adjacent teeth in a single edentulous space
* Minimal Bone Height: Not less than 10 mm
* Residual Alveolar Ridge: Healthy and well-formed, covered with firm mucosa
* Periodontal Health: Absence of signs of periodontal bone loss or significant soft tissue .loss in teeth adjacent to the implant site
* Inter-arch Space: Adequate, exceeding 7 mm

Exclusion Criteria:

* Cooperation: Uncooperative patients
* Pregnancy: Individuals with known pregnancies
* Parafunctional Habits: Abnormal parafunctional habits such as bruxism and clenching
* Systemic Illnesses: Patients with systemic illnesses that could disrupt healing
* Medication: Individuals receiving systemic corticosteroids or other drugs impacting .osseointegration or post-operative healing
* Smoking: Smokers consuming more than 10 cigarettes per day
Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate

Has the maternal KIR haplotype an impact in pregnancy, miscarriage and live birth rates per embryo transfer in donor oocytes -ART by paternal and oocyte donor HLA-C?

The combination of maternal KIR haplotype and parental, donors HLA-C, could predict which couple can benefit for the selection of single embryo transfer (SET)/double embryo transfer (DET), or donor selection by HLA-C in ART, in order to increase the live birth rate (LBR)/cycle since HLA-C1/C1 donors are predicted to be safer and C2/C2 males or oocyte donors may be mor "dangerous" as identified by epidemiological studies

Eligibility Criteria:
Inclusion Criteria:

* BMI between 19 - 27 kg/m2
* Blastocyst embryo transfer previous.
* Normal karyotype, thrombophylic and immunological results.
* Normal clinical history, viral serology, hormonal analysis (TSH, T4, prolactin, estrogen, progesterone), spermiogram, sperm FISH and pelvic ultrasound results.

Exclusion Criteria:

* Pregnancy women.
* Psychiatric disorders.
* Uterus alterations.
* Polycystic ovary syndrome
* Genetic and autoimmune diseases.
* Infectious diseases.
* Corticoid and immunosuppressant treatments previous.
Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis

This is an experimental study, prospective, comparative. This clinical trial is randomized and double-blind, Residronate versus placebo.

The study aims to demonstrate the effectiveness of risedronate in pain management, after 18 month of traitment, in patients undergoing aseptic joint prosthesis loosening. 2 groups were compared with a 1: 1 ratio. The first group receives active drug (risedronate 75mg) and the second a placebo.

Patients are treated during 18 months: 1 tablet residronate/placebo per os two consecutive days each month.

Evaluations are planned evry 6 months.


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects, 18 years of age or older.
* Written informed consent
* Subjects with cemented or not cemented total hip prothesis (for primitive or secondary coxarthrosis)
* Painful aseptic loosening
* Subject has pain 4 or greater on a 10 point Visual Pain Rating scale
* For subject woman of reproductive age, they must use reliable method(s) of contraception and/or abstinence, for the duration of therapeutic product exposure.

Exclusion Criteria:

* Subjects with septic loosening of hip prosthesis

  . Subjects with bilateral disease
* Subjects with implant mobility associated with pre-operative and intraoperative loosening
* Subjects under anti-osteoporotic treatment
* Subjects having stopped a biphosphonate traetment for less than one year
* Subjects with known allergy or sensitivity to any of the components in the study medication.

  * Subjects with Hypocalcemia
  * Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
  * Subjects with severe kidney failure ( creatinine \< 30 ml/min)).
  * Subjects participation in another research study
  * Subjects with previous osteonecrosis of the jaw
Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants

Regional tissue oxygenation (rStO2) can be monitored by near-infrared spectroscopy. The investigators planned a SafeBoosC phase II trial to test if a reduction of the burden of hyper- and hypoxia can be accomplished during the first three days of life in infants born before 28 completed weeks of gestation. The investigators developed a treatment guideline and a randomised trial design to evaluate if cerebral rStO2 spent out of range in %hours can be reduced by 50%. The present trial is a non-randomised pilot study of the intervention in 10 infants.


Eligibility Criteria:
Inclusion Criteria:

* gestational age at birth less than 28 completed weeks
* cerebral oximeter in place at 3 hours after birth

Exclusion Criteria:

* decision not to provide full life support
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.


Eligibility Criteria:
Inclusion Criteria:

* Subject must be 50 years of age or older, of either sex, and of any race/ethnicity.
* Subject must have a clinical history of ragweed-induced allergic rhinoconjunctivitis with or without asthma.
* Subject must have a positive skin prick test response to Ambrosia artemisiifolia at the Screening Visit
* Subject must have a forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at the Screening Visit and at Randomization.
* A subject's clinical laboratory tests, electrocardiogram (ECG) and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator.

Exclusion Criteria:

* Subject with asthma who requires inhaled corticosteroids for the treatment of their asthma during the study period.
* Subject requiring anti-allergy medications during the time period from randomization to study completion.
* Subject who has received an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).
* Subject with a history of anaphylaxis with cardiorespiratory symptoms.
* Subject with a history of chronic urticaria or angioedema.
* Subject with current severe atopic dermatitis.
* Female subject who is breastfeeding, pregnant, or intending to become pregnant.
* Subject with a history of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine.
* Subject with a history of self-injectable epinephrine use.
Efficacy and Safety of Acupuncture for Degenerative Lumbar Spinal Stenosis

Degenerative Lumbar spinal stenosis (DLSS) is a major problem for public health and the primary reason the older seek lumbar spine surgery. Acupuncture is safe and maybe effective for DLSS but the evidence is poor. Therefore, an objective assessment of acupuncture efficacy is critical for making informed decisions about its appropriate role for patients. A total of 80 participants meet prior inclusion criteria will be recruited. The participants will be allocated to acupuncture group or placebo needle (unpenetrated acupuncture) group randomly. Twenty-four treatments will be provided over 8 weeks. The primary change of Modified Roland-Morris Disability Questionnaire (RMDQ) and secondary outcomes including the change of Number Rating Scale (NRS); the change of Self-paced Walking test (SPWT); the change of Swiss Spinal Stenosis Questionnaire (SSSQ); the expectations that acupuncture might help participants with DLSS. All outcomes will be assessed at baseline, and/or after 4, 8, 20 and 32 weeks. Statistical analysis will include independent sample t-test, Chi-squared test and non-parametric test. The investigators hope the result of this trial will clarify the value of acupuncture for DLSS and help clinicians make proper decisions.


Eligibility Criteria:
Inclusion Criteria:

Participants who meet all of the following conditions will be considered for enrollment. The inclusion criteria are as follows:

1. Pain in the low back, buttock, and/or lower extremity with standing, walking and/or spinal extension. (Using NRS questionnaire to measure pain symptoms, and pain measured by NRS ≥ 4.)
2. Roland-Morris score of at least 7.
3. Mild-moderate-severe lumbar central canal spinal stenosis identified by MRI or CT scan.
4. Lower extremity symptoms consistent with neurogenic claudication.
5. Age 50 to 80 years old.
6. Signed the consent and take part in this trial of his/her willing.

Exclusion Criteria:

1. Congenital stenosis of vertebral canal, serious indications of DLSS (such as segmental muscular atrophy, bowel and bladder disturbances), spinal nerve root canal stenosis, lumbar spondylolysis, lumbar tuberculosis, lumbar vertebral tumors, and vertebral body compression fracture.
2. Spinal instability requiring surgery.
3. Severe vascular, pulmonary or coronary artery disease that limits ambulation including recent myocardial infarction.
4. Participants who have cognitive impairment that may render the subject unable to give informed consent or provide accurate data.
5. Clinical co-morbidities that could interfere with the collection of data concerning pain and function.
6. Acupuncture within the past 30 days.
7. Administered pain control drugs during the week prior to the baseline assessment (e.g.,non-steroidal anti-inflammatory drugs or herbal anti-inflammatory agents).
Size Progression of Macular Degeneration After Cataract Surgery

The purpose of this study was to find out if in patients with non-exudative age-related macular degeneration (AMD), randomly assigned to cataract surgery, any AMD size progression or progression to exudative AMD could be detected 6 months after surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients with cataract and non-exudative age-related macular degeneration

Exclusion Criteria:

* Patients with retinal pathologies other than AMD, exudative AMD, progressive glaucoma, myopia \> 10 diopters, panretinal laser treatment, former cataract or vitreoretinal surgery, were excluded.
Choice of Palliative Procedures for Pulmonary Atresia With Ventricular Septal Defect Patients

The aim is to compare effective growth true hypoplastic pulmonary arteries using Right Ventricle Outflow Tract Reconstruction by femoral allogenic vein valve conduit and systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)

The use of femoral allogenic vein valve conduit for Right Ventricle Outflow Tract Reconstruction is good alternative systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt). Main advantages is straight, symmetrical, pulsating, systolic blood flow in hypoplastic pulmonary artery, which stimulate growth and prepares for a radical repair. Taking into account the absence randomized studies in this area of medicine, providing investigation evaluating parameters of safety for both methodics is very actual.

Eligibility Criteria:
Inclusion criteria

Patients who met the following criteria were included:

* Patients with PA-VSD type A and B (by Tchervenkov) scheduled for palliative surgery
* Age less than one year
* Confluent pulmonary artery
* Nakata Index ≤ 120 mm2/m2. Exclusion criteria

Patients who met any of the following criteria were excluded:

* Discordant atrioventricular and/or discordant ventriculo-arterial connections
* Concomitant pathology (pneumonia, brain damage, or enterocolitis)
* Genetic syndromes (DiGeorge, Alagille, VACTER, CHARGE)
* Scheduled MAPCA unifocalisation
* Anomalous coronary arteries
* Other surgical approaches (complete primary repair, primary unification of pulmonary blood flow, stenting RVOT, or patent ductus arteriosus, radiofrequency pulmonary valve perforation).
Long-Term Respiratory Muscle Strength in Young COVID-19 Patients

The coronavirus disease 2019 (COVID-19) is a highly contagious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a multisystem disease and therefore presents a variety of symptoms in the acute phase, such as fever, dry cough, fatigue, sore throat, loss of taste or smell, shortness of breath, nasal congestion, chest pain, muscle or joint pain, headache, and nausea.

COVID-19 primarily affects the respiratory functions of individuals. Although this situation is more difficult in hospitalized patients, it also causes severe effects in individuals who recover with home medication. It is thought that this damage caused by COVID-19 may cause permanent effects on individuals in the long term. During the COVID-19 period, individuals also had to maintain an inactive lifestyle due to quarantine. This decrease in physical activity capacity also causes permanent damage to the respiratory functions of individuals. In addition, studies have focused on this population, as COVID-19 usually affects older individuals. However, considering that young people are also exposed to the COVID-19 virus, the effect on respiratory functions in these individuals should also be examined. Combined with the available information on pulmonary functions, there is insufficient evidence about extrapulmonary features in post-COVID-19 patients who survive mild illness in the long term. It is also necessary to examine whether there is permanent damage to extrapulmonary features such as peripheral muscle strength in these individuals.

Therefore, in our study, it is aimed to examine the long-term results of respiratory functions, respiratory muscle strength and peripheral muscle strength of young individuals who recovered from COVID-19 and recovered from mild disease.


Eligibility Criteria:
Inclusion Criteria:

Patients:

* diagnosed with COVID-19, with a positive polymerase chain reaction (PCR) test
* at least six months ago (long term)
* non-hospitalization due to COVID-19
* non-smoker / for ex-smokers with 10 pack x years or less of smoking
* not continuing any regular physical activity program

Controls:

* non-smoker / for ex-smokers with 10 pack x years or less of smoking,
* not continuing any regular physical activity program
* willing to participate to the study

Exclusion Criteria:

* receiving inpatient or intensive care treatment due to COVID-19
* having acute infection
* previous pulmonary resection or cardiac surgery
* having lung or heart comorbidities such as asthma
* chronic obstructive pulmonary disease (COPD) and heart failure
* uncontrolled hypertension
* history of malignancy
* neurological disease (e.g., Alzheimer, Multiple Sclerosis, Parkinson)
* rheumatologic diseases
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control. The study is a multicenter, US and Canadian, randomized, double-blind, 3-parallel-group, placebo- and escitalopram-controlled, Phase III study consisting of four segments (A, B, C and D). Segment A is a 1-week, placebo, single-blind period. Segment B is an 8-week, double-blind period. Segment C is an optional 18-week double-blind extension period. Segment D is a 1-week safety follow-up period after study drug discontinuation or early termination (during Segment B or C).

To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control. The present study is an 8-week, double-blind, placebo- and escitalopram-controlled, randomized, parallel-group study. A 1-week, placebo, single-blind period precedes the 8-week randomized treatment period and an optional 18-week, double-blind extension period follows the randomized treatment period. A Safety Follow up Visit is scheduled 1 week after the acute and extension period, or early termination. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), an approved treatment for MDD, is chosen as a positive control agent in this study. The dose of 10 mg is within the approved dose range with no need for dose adjustment in elderly patients. This trial is designed to formally compare the efficacy, safety, and tolerability of SR58611A to placebo. Escitalopram is used as a positive control.

Eligibility Criteria:
Inclusion Criteria:

Main inclusion criteria:

* 1. Out-patients, 18 year and older.
* 2. Major Depressive Disorder (MDD) with a recurrentMajor Depressive Episode (MDE) according to DSMIV-TR criteria
* 3. Duration of current episode is at least of 6 weeksunless severity of symptoms justifies shorter duration.
* 4. Patients have been treated or hospitalized for aprevious episode, or a previous episode requiredantidepressant treatment(s) at the recommended doselevel for a continuous total duration of at least 2months.

Exclusion Criteria:

Main exclusion criteria:

* 1. Patients at immediate risk for suicidal behavior
* 2. Patients with a MDE with psychotic features, catatonic features, seasonal pattern or postpartum onset
* 3. The duration of the current depressive episode is greater than 2 years
* 4. Patients whose current depressive episode is secondary to a general medical condition
* 5. Patients with a lifetime history of (1) bipolar disorder, (2) psychotic disorder, (3) antisocial personality disorder
* 6. Patients who have received non-pharmacologic, somatic treatments for psychiatric disease
* 7. Patients who have initiated, stopped, or changed the frequency or nature of psychotherapy within 3 months prior to screening
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment. The study will also look at the amounts of study drug in your blood. There will be 24 participants in this study; 12 of them will have severe renal impairment and not be on hemodialysis and 12 of them will be on hemodialysis.

All participants in this study will take PF-07321332 (nirmatrelvir)/ritonavir by mouth for 5 days. During this time, they will have to collect blood samples to measure the study drug levels in their blood. After taking the study drug for 5 days, the participants will have follow-up visits for about another 28 days for a total of about 34 days in the study. The study team will check how each participant is doing during regular visits at the study clinic.


Eligibility Criteria:
Inclusion Criteria:

* Covid-19 infection
* Severe kidney disease (on hemodialysis or not on hemodialysis)

Exclusion Criteria:

* Hospitalized
* Take medications that are not allowed
* Renal transplant patients
* HIV infection

This is not a complete list. Other inclusion and exclusion criteria may apply.